Journal article

Risperidone versus placebo for schizophrenia.

Ranganath D Rattehalli, Mahesh B Jayaram, Michael Smith

Cochrane Database Syst Rev | Published : 2010


BACKGROUND: Risperidone is the first new generation antipsychotic drug made available in the market in its generic form. OBJECTIVES: To examine the clinical effects of oral risperidone for people with schizophrenia and schizophrenia-like psychoses in comparison with placebo. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (February 2008), references of all included studies, and contacted industry and authors of included studies for relevant studies and data. SELECTION CRITERIA: Randomised clinical trials comparing oral risperidone with placebo treatments for people with schizophrenia and/or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: Two reviewers ind..

View full abstract

University of Melbourne Researchers

Citation metrics